Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Chlorotoxin-CD28-CD3z-CD19t CART cells |
Synonyms | |
Therapy Description |
Chlorotoxin-CD28-CD3z-CD19t CART cells consist of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing a CD28 co-stimulatory domain linked to the CD3zeta chain, a truncated CD19 (CD19t), a G4-Fc (EQ) immunoglobulin spacer, and a matrix metalloproteinase-2 (MMP-2) targeting chlorotoxin peptide, which potentially interferes with chloride transport and remodeling of extracellular matrix, and may induce cytotoxicity against tumor cells expressing MMP-2 and limit tumor cell spreading (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Chlorotoxin-CD28-CD3z-CD19t CART cells | Chlorotoxin (EQ)-CD28-CD3zeta-CD19t CART cell | Chlorotoxin-CD28-CD3z-CD19t CART cells consist of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) containing a CD28 co-stimulatory domain linked to the CD3zeta chain, a truncated CD19 (CD19t), a G4-Fc (EQ) immunoglobulin spacer, and a matrix metalloproteinase-2 (MMP-2) targeting chlorotoxin peptide, which potentially interferes with chloride transport and remodeling of extracellular matrix, and may induce cytotoxicity against tumor cells expressing MMP-2 and limit tumor cell spreading (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04214392 | Phase I | Chlorotoxin-CD28-CD3z-CD19t CART cells | Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma | Recruiting | USA | 0 |